1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2, 3-dioxygenase (IDO) is an inflammatory cytokine-inducible rate-limiting enzyme of the tryptophan (Trp) catabolism, which is involved in the inhibition of intracellular pathogen replication as well as in immunomodulation. To date, three types of tryptophan-metabolizing enzymes have been identified: IDO1, IDO2 and tryptophan 2,3-dioxygenase 2.

IDO is an intracellular enzyme that is constitutively expressed in several human and mouse cells. Being present in innate immune cells, such as Mos and dendritic cells (DCs), IDO catalyzes the initial rate-limiting step of tryptophan (Trp) catabolism, thus leading to the production of immunoregulatory catabolites (collectively known as kynurenines).

The IDO gene promoter contains multiple sequence elements that confer responsiveness to proinflammatory mediators, thereby demonstrating the strong correlation between inflammation and induced IDO expression.

Cat. No. 상품명 효과 Purity Chemical Structure
  • HY-112164
    IACS-8968
    Inhibitor 98.46%
    IACS-8968 (IDO/TDO Inhibitor) is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
    IACS-8968
  • HY-139204
    BMS-986242
    Inhibitor 98.85%
    BMS-986242 is an orally active, potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor. BMS-986242 can be used for the research of cancer.
    BMS-986242
  • HY-N2463
    Kushenol E
    Inhibitor
    Kushenol E is a class of flavonoids isolated from Sophora flavescens and is a non-competitive indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC50 of 7.7 µM and a Ki of 9.5 µM, has anti-tumor activity.
    Kushenol E
  • HY-151093
    IDO2-IN-1
    Inhibitor 98.10%
    IDO2-IN-1 is an orally active and potent Indoleamine 2,3-dioxygenase 2 (IDO2) inhibitor with an IC50 value of 112 nM. IDO2-IN-1 can be used for inflammatory autoimmunity research.
    IDO2-IN-1
  • HY-79531
    IDO-IN-1
    Inhibitor 98.14%
    IDO-IN-1 is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC50 of 59 nM.
    IDO-IN-1
  • HY-78699
    2-Hydrazinobenzothiazole
    Inhibitor 99.95%
    2-Hydrazinobenzothiazole is a potent IDO1 inhibitor with an IC50 of 8 μM. 2-hydrazinobenzothiazole interacts with the IDO1 haem through hydrazine. 2-hydrazinobenzothiazole has the potential for immune system related diseases research.
    2-Hydrazinobenzothiazole
  • HY-153764
    IDO-IN-18
    Inhibitor
    IDO-IN-18 (Compound 00815) is an IDO inhibitor. IDO-IN-18 can be used for research of immunosuppression associated infectious or cancer diseases.
    IDO-IN-18
  • HY-178011
    IDO1-IN-28
    Inhibitor 99.89%
    IDO1-IN-28 (Compound MQ-1) is a Apo-IDO1 inhibitor with an IC50 of 1.29  μM. IDO1-IN-28 selectively targets apo-IDO1 and disrupts heme binding. IDO1-IN-28 can be used for cancers research.
    IDO1-IN-28
  • HY-111540B
    (S)-LY-3381916
    Inhibitor 99.06%
    (S)-LY-3381916 ((S)-IDO1-IN-5; Example 1B) is an active S-isomer of LY-3381916. (S)-LY-3381916 binds to IDOL with an IC50 value less than 1.5 µΜ. LY-3381916 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.
    (S)-LY-3381916
  • HY-18769
    BMS-978587
    Inhibitor 99.92%
    BMS-978587 (IDO-IN-4) is an indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, extracted from patent WO2014150677A1, Compound example 1 enantiomer 1.
    BMS-978587
  • HY-111540A
    (Rac)-LY-3381916
    Inhibitor 99.12%
    (Rac)-LY-3381916 ((Rac)-IDO1-IN-5; Example 1) is a racemate of LY-3381916. LY-3381916 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.
    (Rac)-LY-3381916
  • HY-18770
    IDO-IN-5
    Inhibitor 99.90%
    IDO-IN-5 (NLG-1489) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, compound 1489, has an IC50 of 1-10 μM.
    IDO-IN-5
  • HY-18770C
    IDO-IN-8
    Inhibitor 99.99%
    IDO-IN-8 (NLG-1487) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, compound 1487, has an IC50 of 1-10 μM.
    IDO-IN-8
  • HY-151978
    ZC0109
    Inhibitor 99.86%
    ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 (TrxR1) with IC50s of 50 nM and 3.0 μM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis.
    ZC0109
  • HY-173066
    NU227326
    Degrader
    NU227326 is a blood-brain barrier penetrant IDO1 PROTAC degrader, with a DC50 of 4.5 nM in HiBiT degradation assays. NU227326 degrades IDO1 in U87 and GBM43 cells, with DC50 values of 7.1 nM and 11.8 nM, respectively (WB assays). NU227326 is applicable to research related to glioblastoma, prostate cancer, triple-negative breast cancer, pancreatic cancer, and ovarian cancer.
    NU227326
  • HY-16987
    IDO-IN-3
    Inhibitor 98.97%
    IDO-IN-3 is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC50 of 290 nM.
    IDO-IN-3
  • HY-112164B
    IACS-8968 S-enantiomer
    Inhibitor 98.43%
    IACS-8968 (S-enantiomer) is the S-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
    IACS-8968 S-enantiomer
  • HY-Y1322S
    Triphenyl phosphate-d15
    Activator 99.74%
    Triphenyl phosphate-d15 is the deuterium labeled Triphenyl phosphate. Triphenyl phosphate is an orally active, blood-brain barrier-permeable aryl organophosphate flame retardant and endocrine disruptor. Triphenyl phosphate disrupts mitochondrial dynamic balance through oxidative stress, induces excessive mitophagy and apoptosis, and ultimately leads to myocardial fibrosis. In the brain, Triphenyl phosphate activates the NF-κB inflammatory pathway by disrupting the gut microbiota, alters tryptophan metabolism and elevates neurotoxins, thereby inducing anxiety- and depression-like behaviors. In the skeletal and reproductive systems, Triphenyl phosphate inhibits osteoblast differentiation and induces germ cell apoptosis by suppressing the MAPK/ERK pathway and activating the JNK signal, respectively. In adipose and placental tissues, Triphenyl phosphate promotes lipid accumulation by activating the PI3K/AKT-PPARγ axis, and disrupts placental metabolism via the MAOA/ROS/NF-κB cascade, impairing neurodevelopment of offspring.
    Triphenyl phosphate-d<sub>15</sub>
  • HY-N0430
    Coptisine
    Inhibitor
    Coptisine is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine is a reversible, uncompetitive IDO inhibitor with a Ki of 5.8 μM and an IC50 of 6.3 μM. Coptisine suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine can be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease.
    Coptisine
  • HY-139205
    BMT-297376
    Inhibitor 99.14%
    BMT-297376 is an optimized derivative of Linrodostat (HY-101560). BMT-297376 inhibits IDO1 and the ubiquinone (Q) site of mitochondrial respiratory chain complex I. BMT-297376 is suitable for tumor immunology-related research.
    BMT-297376
Cat. No. 상품명 / Synonyms Species Source
Cat. No. 상품명 / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.